Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119822
Chunk: 142

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 142
---
 to ZTlido, GLOPERBA, ELYXYB or our product candidates, including but 
 not limited to clinical trial requirements for approvals;                                                      |

| • |     | legal disputes or other developments relating to proprietary rights, including patents, litigation matters and                                                                                                                             
 our ability to obtain patent protection for ZTlido, GLOPERBA, ELYXYB or our product candidates, government investigations and the results of any proceedings or lawsuits, including, but not limited to, patent or stockholder litigation; |

| • |     | our decision to initiate a clinical trial, not initiate a clinical trial or to terminate an existing clinical 
 trial;                                                                                                        |

| • |     | our dependence on third parties; |

| • |     | announcements of the introduction of new products by our competitors; |

| • |     | market conditions and trends in the pharmaceutical and biotechnology sectors; |

| • |     | announcements concerning product development results or intellectual property rights of others; |

| • |     | future issuances of common stock or other securities; |

| • |     | the recruitment or departure of key personnel; |

| • |     | failure to meet or exceed any financial guidance or expectations regarding product development milestones that we 
 may provide to the public;                                                                                        |

| • |     | actual or anticipated variations in quarterly operating results; |

| • |     | our failure to meet or exceed the estimates and projections of the investment community; |

| • |     | overall performance of the equity markets and other factors that may be unrelated to our operating performance or 
 the operating performance of our competitors, including changes in market valuations of similar companies;        |

| • |     | announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or 
 our competitors;                                                                                                  |

| • |     | changes in financial estimates by the Company or by any securities analysts who might cover our stock; |

| • |     | fluctuation of the market values of any of our potential strategic investments; |

| • |     | issuances of debt or equity securities; |

| • |     | compliance with our contractual obligations; |

| • |     | sales of our Common Stock by us or our stockholders in the future; |

| • |     | trading volume of our Common Stock; |

| • |     | ineffectiveness of our internal controls; |

| • |     | publication of research reports about the Company or its industry or positive or negative recommendations or 
 withdrawal